PureCycle Technologies Stock (NASDAQ: PCTTU)

Latest news for PureCycle Technologies (NASDAQ:PCTTU) Stock

PureCycle Technologies Inc holds a license to commercialize the only patented solvent-based purification recycling technology, developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene (PP) into a virgin-like resin. The proprietary process removes color, odor, and other contaminants from recycled feedstock resulting in virgin-like polypropylene suitable for any PP market.

Penny Stocks

Small Cap

Trading Ideas

ALLG

FATBB

IGMS

PCTTU

VLNS

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.

Here are all the stocks halted on a circuit breaker today, according to Benzinga Pro.

8 Stocks Halted In Tuesday&#39;s Session

PureCycle Technologies Inc

<p>Ratings for Pacific Premier Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBI#NASDAQ">PPBI</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Pacific Premier Bancorp, presenting an average target of $26.5, a high estimate of $28.00, and a low estimate of $25.00. Observing a 4.95% increase, the current average has risen from the previous average price target of $25.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200870_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Pacific Premier Bancorp among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Feaster</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Premier Bancorp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Premier Bancorp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Pacific Premier Bancorp's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pacific Premier Bancorp's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PPBI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Pacific Premier Bancorp analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Pacific Premier Bancorp</h2>
<p>Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.</p>
<h3>Key Indicators: Pacific Premier Bancorp's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Challenges:</strong> Pacific Premier Bancorp's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-17.2%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>29.06%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Pacific Premier Bancorp's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.41%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.22%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.18</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

PPBI

Beyond The Numbers: 4 Analysts Discuss Pacific Premier Bancorp Stock

<p>13 analysts have shared their evaluations of Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Braze and provided 12-month price targets. The average target is $61.15, accompanied by a high estimate of $75.00 and a low estimate of $45.00. This current average represents a 3.88% decrease from the previous average price target of $63.62. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200858_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Braze among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$56.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Braze. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Braze compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Braze's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Braze's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BRZE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Braze analyst ratings.</strong></a></p>
<h2>Get to Know Braze Better</h2>
<p>Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail &amp; E-commerce, Media &amp; Entertainment, Financial Services, and Travel &amp; Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates a majority of its revenue from the United States.</p>
<h3>Breaking Down Braze's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Braze displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>26.4%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Braze's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-15.81%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Braze's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-5.17%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Braze's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-2.8%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Braze's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.19</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BRZE

Deep Dive Into Braze Stock: Analyst Perspectives (13 Ratings)

<p>Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 20% leaning bullish and 66% bearish. Among these notable options, 17 are puts, totaling $927,651, and 7 are calls, amounting to $479,810.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $660.0 for UnitedHealth Group during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of UnitedHealth Group stands at 133.33, with a total volume reaching 2,271.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in UnitedHealth Group, situated within the strike price corridor from $300.0 to $660.0, throughout the last 30 days.</p>
<h3>UnitedHealth Group Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200858_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.9</td>
<td>$2.89</td>
<td>$2.9</td>
<td>$620.00</td>
<td>$218.3K</td>
<td style="text-align: right;">673</td>
<td style="text-align: right;">736</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$165.15</td>
<td>$162.9</td>
<td>$162.9</td>
<td>$430.00</td>
<td>$81.4K</td>
<td style="text-align: right;">32</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$31.35</td>
<td>$29.75</td>
<td>$30.06</td>
<td>$580.00</td>
<td>$74.9K</td>
<td style="text-align: right;">349</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$30.15</td>
<td>$29.7</td>
<td>$29.89</td>
<td>$580.00</td>
<td>$74.5K</td>
<td style="text-align: right;">349</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$29.65</td>
<td>$28.9</td>
<td>$29.27</td>
<td>$580.00</td>
<td>$67.1K</td>
<td style="text-align: right;">349</td>
<td style="text-align: right;">221</td>
</tr>
</tbody>
</table>
</p>
<h3>About UnitedHealth Group</h3>
<p>UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.</p>
<p>Having examined the options trading patterns of UnitedHealth Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of UnitedHealth Group</h3>
<ul>
<li>Trading volume stands at 1,384,480, with UNH's price down by -0.14%, positioned at $572.63.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 21 days.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $591.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $591.<br />
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $591.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $591. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

Spotlight on UnitedHealth Group: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Amgen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Amgen.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 43% bullish and 43%, bearish.</p>
<p>Out of all of the special options we uncovered, 10 are puts, for a total amount of $1,298,955, and 6 are calls, for a total amount of $312,382.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $145.0 to $390.0 for Amgen over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Amgen stands at 388.45, with a total volume reaching 3,084.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amgen, situated within the strike price corridor from $145.0 to $390.0, throughout the last 30 days.</p>
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200853_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$20.5</td>
<td>$19.95</td>
<td>$20.03</td>
<td>$330.00</td>
<td>$801.2K</td>
<td style="text-align: right;">590</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$20.15</td>
<td>$20.0</td>
<td>$20.05</td>
<td>$330.00</td>
<td>$188.3K</td>
<td style="text-align: right;">590</td>
<td style="text-align: right;">538</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$190.8</td>
<td>$186.9</td>
<td>$188.7</td>
<td>$145.00</td>
<td>$132.0K</td>
<td style="text-align: right;">40</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.85</td>
<td>$6.85</td>
<td>$7.3</td>
<td>$360.00</td>
<td>$70.0K</td>
<td style="text-align: right;">109</td>
<td style="text-align: right;">96</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$4.1</td>
<td>$3.8</td>
<td>$4.1</td>
<td>$335.00</td>
<td>$52.4K</td>
<td style="text-align: right;">235</td>
<td style="text-align: right;">265</td>
</tr>
</tbody>
</table>
</p>
<h3>About Amgen</h3>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<h3>Present Market Standing of Amgen</h3>
<ul>
<li>With a trading volume of 737,520, the price of AMGN is down by -0.96%, reaching $332.39.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


AMGN

Market Whales and Their Recent Bets on AMGN Options

<p>5 analysts have expressed a variety of opinions on Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Cibus, revealing an average target of $22.3, a high estimate of $25.00, and a low estimate of $20.00. This current average represents a 1.63% decrease from the previous average price target of $22.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200849_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Cibus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Venezia</td>
<td>Alliance Global Partners</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.50</td>
<td>$25.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Venezia</td>
<td>Alliance Global Partners</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cibus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cibus compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Cibus's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cibus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CBUS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cibus analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Cibus's Background</h2>
<p>Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.</p>
<h3>Cibus's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Cibus's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>325.38%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Cibus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-3398.33%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Cibus's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-10.38%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-5.24%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Cibus's debt-to-equity ratio is below the industry average. With a ratio of <b>0.14</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CBUS

Unveiling 5 Analyst Insights On Cibus

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Apollo Global Management</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with APO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Apollo Global Management.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $114,190, and 7 are calls, for a total amount of $2,226,510.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $77.5 to $140.0 for Apollo Global Management over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Apollo Global Management's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Apollo Global Management's significant trades, within a strike price range of $77.5 to $140.0, over the past month.</p>
<h3>Apollo Global Management Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200848_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>APO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.9</td>
<td>$5.5</td>
<td>$5.8</td>
<td>$140.00</td>
<td>$1.1M</td>
<td>1.1K</td>
<td>3.5K</td>
</tr>
<tr>
<td>APO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.9</td>
<td>$5.6</td>
<td>$5.8</td>
<td>$140.00</td>
<td>$870.0K</td>
<td>1.1K</td>
<td>1.5K</td>
</tr>
<tr>
<td>APO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.8</td>
<td>$5.5</td>
<td>$5.8</td>
<td>$140.00</td>
<td>$81.2K</td>
<td>1.1K</td>
<td>2.1K</td>
</tr>
<tr>
<td>APO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.25</td>
<td>$2.15</td>
<td>$2.25</td>
<td>$122.00</td>
<td>$74.4K</td>
<td>0</td>
<td>331</td>
</tr>
<tr>
<td>APO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.35</td>
<td>$2.15</td>
<td>$2.35</td>
<td>$122.00</td>
<td>$39.7K</td>
<td>0</td>
<td>500</td>
</tr>
</tbody>
</table>
</p>
<h3>About Apollo Global Management</h3>
<p>Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Asset Management, Retirement Services, and Principal Investing. It generates maximum revenue from the Retirement Services segment.</p>
<p>Following our analysis of the options activities associated with Apollo Global Management, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Apollo Global Management Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,772,666, with APO's price down by -0.14%, positioned at $125.06.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 36 days.</li>
</ul>
<h3>Professional Analyst Ratings for Apollo Global Management</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $142.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Wells Fargo lowers its rating to Overweight with a new price target of $132.<br />
&#x2A; An analyst from Redburn Atlantic has revised its rating downward to Buy, adjusting the price target to $153. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apollo Global Management options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Behind the Scenes of Apollo Global Management's Latest Options Trends

<p>In the latest quarter, 7 analysts provided ratings for SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.14, a high estimate of $29.00, and a low estimate of $25.00. Marking an increase of 7.96%, the current average surpasses the previous average price target of $25.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200842_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of SLM among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Kaye</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mark Devries</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SLM. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SLM compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of SLM's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of SLM's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SLM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on SLM analyst ratings.</strong></a></p>
<h2>All You Need to Know About SLM</h2>
<p>SLM Corp is the largest student lender in the country. It makes and holds student loans through the guaranteed Federal Family Education Loan Program as well as through private channels. It also engages in debt-management operations, including accounts receivable and collections services, and runs college savings programs.</p>
<h3>Breaking Down SLM's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> SLM's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-3.15%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> SLM's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>48.13%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> SLM's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>12.7%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> SLM's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.87%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.66</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying SLM: Insights From 7 Analyst Reviews

<p>In the last three months, 4 analysts have published ratings on CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for CVB Financial, presenting an average target of $20.5, a high estimate of $21.00, and a low estimate of $20.00. This upward trend is apparent, with the current average reflecting a 6.49% increase from the previous average price target of $19.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200828_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive CVB Financial is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVB Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVB Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of CVB Financial's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CVBF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CVB Financial analyst ratings.</strong></a></p>
<h2>Delving into CVB Financial's Background</h2>
<p>CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.</p>
<h3>Financial Insights: CVB Financial</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> CVB Financial's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-5.24%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> CVB Financial's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>39.7%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> CVB Financial's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.37%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> CVB Financial's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.3%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.24</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CVBF

Where CVB Financial Stands With Analysts

<p>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has outperformed the market over the past 5 years by 18.39% on an annualized basis producing an average annual return of 32.37%. Currently, Moderna has a market capitalization of $24.87 billion. </p>
<p><strong>Buying $100 In MRNA:</strong> If an investor had bought $100 of MRNA stock 5 years ago, it would be worth <strong>$406.92</strong> today based on a price of $64.70 for MRNA at the time of writing.</p>
<h3>Moderna's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200826_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

MRNA

Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today

<p>Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) has outperformed the market over the past 5 years by 30.63% on an annualized basis producing an average annual return of 44.6%. Currently, Broadcom has a market capitalization of $812.52 billion. </p>
<p><strong>Buying $100 In AVGO:</strong> If an investor had bought $100 of AVGO stock 5 years ago, it would be worth <strong>$636.73</strong> today based on a price of $174.55 for AVGO at the time of writing.</p>
<h3>Broadcom's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200821_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AVGO

If You Invested $100 In This Stock 5 Years Ago, You Would Have $600 Today

<p>In the latest quarter, 13 analysts provided ratings for Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $89.23, a high estimate of $105.00, and a low estimate of $74.00. Witnessing a positive shift, the current average has risen by 15.42% from the previous average price target of $77.31.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727200809_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Western Alliance by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Bernard von-Gizycki</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$83.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$74.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Casey Haire</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Western Alliance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Western Alliance compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Western Alliance's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Western Alliance's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WAL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Western Alliance analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Western Alliance</h2>
<p>Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking. Corporate &amp; Other.</p>
<h3>Western Alliance: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Western Alliance displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>4.53%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>32.6%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Western Alliance's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.2%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Western Alliance's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.24%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.1</strong>, caution is advised due to increased financial risk.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Western Alliance: Insights From 13 Analyst Reviews

<p>Raymond James  analyst Frank Louthan   maintains Verizon Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) with a Outperform and raises the price target from $44 to $48.</p>


Price Target

Raymond James Maintains Outperform on Verizon Communications, Raises Price Target to $48

<p><strong>CrowdStrike Holdings, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">marginally lower on Tuesday.</a></p>
<p>Jefferies analyst Joseph Gallo maintained the Buy rating on the stock, raising the price forecast from&nbsp;$315&nbsp;to&nbsp;$345.</p>
<p>Today,<strong> Adam Meyers</strong>, a senior executive at CrowdStrike is set to testify before the U.S. Congress regarding the global IT outage that occurred on July 19.</p>
<p>Meyers is expected to express deep regret about the incident and emphasize his company&#8217;s commitment to preventing a recurrence, <a target="_blank" href="https://www.bbc.com/news/articles/cr54m92ermgo" rel="noreferrer noopener">reported </a>BBC.</p>
<p>The incident, caused by a software update, left stranded travelers and small businesses facing significant sales losses. The update affected millions of computers running Microsoft systems worldwide.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39873706/crowdstrike-outage-impacted-less-than-1-of-windows-devices-but-still-managed-to-wreak-havoc-report" rel="noreferrer noopener">CrowdStrike Outage Impacted Less Than 1% Of Windows Devices But Still Managed To Wreak Havoc: Report</a></strong></p>
<p>According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, CRWD stock has gained over 81% in the past year. Investors can gain exposure to the stock via&nbsp;REX AI Equity Premium Income ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIPI#NASDAQ">AIPI</a>).</p>
<p>In a blog&nbsp;<a target="_blank" href="https://blogs.microsoft.com/blog/2024/07/20/helping-our-customers-through-the-crowdstrike-outage/" rel="noreferrer noopener">post</a> in July, Microsoft highlighted the widespread impact of the outage, attributing it to the extensive use of CrowdStrike by businesses running critical services.</p>
<p>&#8220;This incident demonstrates the interconnected nature of our broad ecosystem — global cloud providers, software platforms, security vendors and other software vendors, and customers,&#8221; Microsoft shared in the post.</p>
<p>&#8220;It&#8217;s also a reminder of how important it is for all of us across the tech ecosystem to prioritize operating with safe deployment and disaster recovery using the mechanisms that exist.&#8221;</p>
<p><strong>Related: <a target="_blank" href="https://www.benzinga.com//node/40657754" rel="noreferrer noopener">CrowdStrike Stock Nears Death Cross As Delta Dispute Escalates</a></strong></p>
<p>Security researcher Troy Hunt had <a target="_blank" href="https://x.com/troyhunt/status/1814198760387596407" rel="noreferrer noopener">described </a>it as the &#8220;largest IT outage in history,&#8221; especially since tech companies managed <a target="_blank" href="https://www.benzinga.com/news/24/07/39870313/microsoft-crowdstrike-issue-caused-largest-it-outage-in-history-showing-how-much-we-depend-on-a-hand" rel="noreferrer noopener">to avoid the &#8220;Y2K&#8221; issue.</a></p>
<p>Recently, CrowdStrike revised its revenue and <a href="https://www.benzinga.com//node/40620121" target="_blank" rel="noreferrer noopener">profit projections downward.</a></p>
<p><strong>Price Action: </strong>CRWD shares are trading lower by 1.09% to $289.94 at last check Tuesday.</p>
<p><em>Photo via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/24/09/41008403/consumer-confidence-tumbles-as-concerns-over-labor-market-grow-odds-rise-for-50-b" target="_blank" rel="noreferrer noopener">Consumer Confidence Tumbles As Concerns Over Labor Market Grow, Odds Rise For 50-Basis-Point Interest Rate Cut In November</a></strong></li>
</ul>
<p><strong><em>Disclaimer</em></strong><em>: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>


Equities

Movers

Media

General

AIPI

CRWD

What's Going On With CrowdStrike Stock Today?

<p>Raymond James  analyst Wilma Burdis   maintains Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) with a Strong Buy and raises the price target from $228 to $250.</p>


Raymond James Maintains Strong Buy on Reinsurance Gr, Raises Price Target to $250

<p>Raymond James  analyst Tim Thein   upgrades CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) from Market Perform to Outperform and announces $14 price target.</p>


Upgrades

Raymond James Upgrades CNH Industrial to Outperform, Announces $14 Price Target

<p><strong>THOR Industries, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tho#NYSE">THO</a>) has solidified its leadership in recreational vehicle (RV) innovation by introducing the THOR Test Vehicle, the world&#39;s first hybrid Class A motorhome. Built on an electric vehicle&nbsp;platform developed in collaboration with EV manufacturer Harbinger, the vehicle features a low-emissions gasoline range extender capable of recharging the battery system, with an estimated range of 500 miles.</p>
<p>The hybrid RVs will be available in 2025 through the THOR family of companies and are expected to meet Near-Zero Emission Vehicle standards under Advanced Clean Truck legislation adopted by the California Air Resources Board. Per Bob Martin, president and CEO of THOR Industries, the innovative hybrid platform and the ongoing partnership with Harbinger underscore THOR&#39;s leadership and introduce significant product differentiation.</p>
<p>The THOR Test Vehicle is uniquely designed for RV range requirements, exclusively for THOR. This is the first electrified chassis specifically tailored for Class A motorhomes. This platform aims to reduce range anxiety while enhancing travel freedom and sustainability. The hybrid chassis is powered by a 140-kWh battery pack, supplemented by a gasoline range extender and solar rooftop. Its 800-volt electrical system enables fast charging at DC Fast Charger stations, which aids extended travel. Charging can also occur at campsites, through the range extender, or via solar energy to provide flexibility for both on-road and off-grid use.</p>
<p>The hybrid platform can serve as a backup power source for homes and may eventually allow users to sell excess energy back to the grid. The electric powertrain delivers exceptional acceleration and torque, providing up to twice the torque of a diesel engine, ensuring strong highway performance on mountain roads and tough terrain. Harbinger&#39;s chassis design includes all the core systems of an EV, such as the drivetrain, high-voltage battery system, steering and brakes. With a double-wishbone front suspension, a steer-by-wire system and an advanced driver assistance system, the chassis ensures a smooth and safe ride, even for large vehicles.</p>
<p>The THOR Test Vehicle is available for test drives by RV dealers on the THOR RV Experience Track at the Elkhart Dealer Open House, the largest dealer event in North America, from Monday, Sept. 23, 2024, in Elkhart, IN. Dealers will get to experience this future-forward RV and contribute to its market launch.</p>
<h2>THO&#39;s Zacks Rank &amp; Key Picks</h2>
<p>THO currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the auto space are <strong>Dorman Products, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dorm#NASDAQ">DORM</a>), <strong>Blue Bird Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blbd#NASDAQ">BLBD</a>) and <strong>Douglas Dynamics, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/plow#NYSE">PLOW</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.</p>
<p>The consensus estimate for DORM&#39;s 2024 sales and earnings suggests year-over-year growth of 3.71% and 35.46%, respectively. EPS estimates for 2024 and 2025 have improved 51 cents and 37 cents, respectively, in the past 60 days.</p>
<p>The Zacks Consensus Estimate for BLBD&#39;s 2024 sales and earnings suggests year-over-year growth of 17.58% and 215.89%, respectively. EPS estimates for 2024 and 2025 have improved 65 cents and 80 cents, respectively, in the past 60 days.</p>
<p>The Zacks Consensus Estimate for PLOW&#39;s 2024 earnings suggests year-over-year growth of 60.4%. EPS estimates for 2024 have improved 15 cents in the past 60 days.</p>
<p><a href="https://www.zacks.com/stock/news/2340663/thor-harbinger-introduce-world-s-first-hybrid-class-a-motorhome?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2340663">To read this article on Zacks.com click here.</a></p>


Earnings

Mid Cap

Tech

BLBD

DORM

PLOW

THOR & Harbinger Introduce World's First Hybrid Class A Motorhome

<p>Citigroup  analyst Jeff Chung   maintains Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) with a Neutral and raises the price target from $21.6 to $25.5.</p>


Citigroup Maintains Neutral on Li Auto, Raises Price Target to $25.5

<p>Raymond James  analyst Josh Beck   reinstates DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Outperform and announces $155 price target.</p>


Initiation

DASH

Raymond James Reinstates Outperform on DoorDash, Announces $155 Price Target

<p>Raymond James  analyst Josh Beck   reinstates Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Market Perform.</p>


LYFT

Raymond James Reinstates Market Perform on Lyft

<p>Shares of <strong>Baidu Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) surged 6.15% to $93.71 Tuesday afternoon, benefiting from the sweeping monetary stimulus announced by the <strong>People&#8217;s Bank of China (PBoC)</strong>.</p>
<p>The central bank's decision to <a href="https://www.benzinga.com/markets/asia/24/09/41003814/chinese-stocks-jump-as-central-bank-unveils-major-stimulus-to-spur-economy-a-step-in-the-right-direc">aggressively cut</a> both the <strong>reserve requirement ratio (RRR)</strong> and policy rates injected new optimism into China&#8217;s economy, sparking a broad rally in Chinese equities.</p>
<p><strong>What Happened:</strong> Baidu, known as the <strong>&#8220;Google of China,&#8221;</strong> is a key player in the country's internet and artificial intelligence sectors. Shares rose sharply as investors anticipated that the substantial liquidity boost and policy rate cuts would not only help revive economic growth but also spur demand for the company's diverse range of digital services, which include search, cloud computing and AI-driven solutions.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/41008403/consumer-confidence-tumbles-as-concerns-over-labor-market-grow-odds-rise-for-50-b">Consumer Confidence Tumbles As Concerns Over Labor Market Grow, Odds Rise For 50-Basis-Point Interest Rate Cut In November</a></strong></p>
<p>The PBoC&#8217;s move to cut the RRR by 50 basis points, freeing up around $140 billion in liquidity for commercial banks, has the potential to improve credit availability across sectors. This infusion of capital into the economy is expected to particularly benefit large technology firms like Baidu, which rely on a strong consumer base and business spending for digital advertising and cloud services revenue. </p>
<p>With more liquidity in the system, businesses are likely to increase their spending on Baidu&#8217;s advertising platform and AI-powered enterprise solutions, boosting the company's revenue streams.</p>
<p><strong>What Else:</strong> Additionally, Baidu's expansion into autonomous driving and AI cloud infrastructure aligns with China&#8217;s long-term technological ambitions, making the company well-positioned to capitalize on any government-led investment in innovation and digital infrastructure. </p>
<p>The easing of mortgage rates and repo rate cuts are also expected to stabilize China&#8217;s real estate sector, further bolstering consumer confidence. Increased consumer spending could translate into higher engagement on Baidu's platforms, from search engine usage to its mobile ecosystem.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/asia/24/09/41007724/gold-breaks-records-on-chinas-policy-stimulus-mining-metal-stocks-exhibit-strongest-1-day-rally-in-2">Gold Breaks Records On China&#8217;s Policy Stimulus: Mining, Metal Stocks Exhibit Strongest 1-Day Rally In 2024</a></strong></p>
<h2 class="wp-block-heading">Is BIDU A Good Stock To Buy?</h2>
<p>An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. </p>
<p>For example, for Baidu, you'll notice that earnings in its last quarter grew 12.02% <a href="https://www.benzinga.com/quote/BIDU/earnings">source</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio. </p>
<p>On the valuation side, Baidu's price to earnings ratio &#8211; a measure of how much an investor pays for the company's earnings &#8211; is compressed 62.55% in the current quarter when compared with last year. That places it below similar businesses Alphabet, Meta Platforms, Pinterest in its sector. You'll need to decide whether that makes it more or less attractive based on how you think the company will perform over time.</p>
<p>There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/BIDU">Baidu's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BIDU has a 52-week high of $136.53 and a 52-week low of $79.69.</p>


BIDU

Why Baidu Stock Is Rising

PureCycle Technologies- Walking A Tightrope Amidst Execution Challenges

Undercovered Dozen: Burberry, Vinci SA, Lyft, PureCycle +

ADMA

AUTL

BBRYF

BURBY

CDDRF

LQDA

NPICF

NPIFF

PCTTW

VCISF

VCISY

Press Releases

NATIONALLY RANKED ROSEN LAW FIRM Encourages PureCycle Technologies, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PCT, PCTTW, PCTTU

ROSEN, A TOP RANKED LAW FIRM, Encourages PureCycle Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCT, PCTTW, PCTTU

PCT FINAL DEADLINE ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages PureCycle Technologies, Inc. Investors to Secure Counsel Before Important November 28 Deadline in Securities Class Action – PCT, PCTTW, PCTTU

PCT DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages PureCycle Technologies, Inc. Investors with Losses to Secure Counsel Before Important November 28 Deadline in Securities Class Action - PCT, PCTTW, PCTTU

PCT FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages PureCycle Technologies, Inc. Investors to Secure Counsel Before Important November 28 Deadline in Securities Class Action - PCT, PCTTW, PCTTU

AdvanSix

Braskem

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings

Cabot

Core Molding Technologies Inc Common Stock

Core Molding Technologies

Crown Electrokinetics Corp. - Common Stock

Crown ElectroKinetics

Gulf Resources

Hawkins

Koppers Hldgs

Kronos Worldwide

Loop Industries

Mativ Holdings

Orion

Olin

Origin Materials, Inc. - Class A Common Stock

Origin Mat

PureCycle Technologies, Inc. - Common stock

PureCycle Technologies

Tantech Hldgs

Tronox Holdings

Trinseo

Westlake

Westlake Chemical Partners LP Common Units representing limited partner interests

Westlake Chemical

<p>A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.</p>

<p>Here are all the stocks halted on a circuit breaker today, <a href="https://benzinga.grsm.io/lukejacobi5348">according to Benzinga Pro</a>.</p>

<p><strong>Target Hospitality Corp </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) halted at 9:36 a.m., shares fell 17.11%, before rebounding off of the lows.</p>

<p>One-day price action: -6.14%</p>

<p><strong>GameStop Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) halted at 9:37 a.m., shares fell 9.07% in the following hour.<br />
One-day price action: -5.11%</p>

<p><strong>AMC Entertainment Holdings Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) halted at 9:38 a.m. after making a 13.37% upside move in four minutes; shares fell 3.36% over the following hour.<br />
One-day price action: +0.34%</p>

<p><strong>Allego NV</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLG#NYSE">ALLG</a>) halted twice after making a 36.02% overall upside move; shares fell 19.03% over the following hour.<br />
One-day price action: -14.44%</p>

<p><strong>Fat Brands Inc Class B </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATBB#NASDAQ">FATBB</a>) halted twice for making a 45% overall upside move; shares settled 2.61% higher over the following hour.<br />
One-day price action: +26.5%</p>

<p><strong>IGM Biosciences Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) halted at 11:09 a.m.; shares made an overall 96.3% upside move for the session.</p>

<p><strong>PureCycle Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTTU#NASDAQ">PCTTU</a>) Halted at 1:21 p.m.</p>

<p>One-day price action: +4.55%&nbsp;</p>

<p><strong>Valens Company Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLNS#NASDAQ">VLNS</a>) halted at 4 p.m.; The company filed&nbsp;for a mixed shelf of&nbsp;up&nbsp;to&nbsp;$150 million.<br />
One-day price action: +2.20%</p>


Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

PureCycle Technologies

News

Latest news for PureCycle Technologies (NASDAQ:PCTTU) Stock

Tuesday, March 29, 2022

People Also Watch